BWAY | Ticker Profile - Titan Protect

BWAY

BrainsWay Ltd.

Healthcare · Medical Devices · NGM

$13.89

Data: 2026-05-15

✓ ETHICAL PASS

MODERATE MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$602M

Total market value of the company

Trailing P/E

83.50

Expensive — high growth expected

Forward P/E

33.65

Based on estimated future earnings — lower means cheaper

Rev Growth

+34.6%

Year-over-year revenue change

Profit Margin

15.6%

How much profit the company keeps from each dollar of revenue

ROE

12.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$16.00

+15% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 3 analysts covering this stock

About BrainsWay Ltd.

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.

https://www.brainsway.com

Country: Israel Employees: 129 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

1.1% PASS

Debt must be below 33% of total assets

Cash Ratio

10.6% PASS

Interest-bearing cash below 33% of assets

Receivables

0.0% PASS

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Valuation

Fair Value Est.

$13.40

What our model estimates this business is worth per share

Margin of Safety

-3.7%

Trading above fair value — no margin of safety

Rating

FAIR VALUE

Overall assessment combining ethics, valuation, and quality

Percentile

95.7th

Ranks in the top 4% of our 13,571 screened universe

Ethical Score

95.6

Valuation Score

36.5

Quality Score

69.0

Combined

N/A

Trading at $15, 12% above fair value of $13. Moderate competitive position. Passes all ethical screens. Ranks better than 82% of screened stocks.

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

1.957

Excellent risk-adjusted returns

Kelly Fraction

0.1227

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

4.526

Returns exceed worst-case losses — strong risk profile

Annual Return

145.9%

Historical annualised return based on price data

Max Drawdown

-32.2%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$17.35

20% below the year high

52W Low

$4.94

181% above the year low

Avg Volume

171,732

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.8

Days it would take all short sellers to cover — higher means more crowded

Short % Float

0.4%

Low short interest — limited bearish positioning

Div Yield

0.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$0.18

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.09

Conservative use of debt — low financial risk

Current Ratio

3.34

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

2.81

Like current ratio but excludes inventory — stricter test

Gross Margin

75.5%

Revenue left after cost of goods — higher means pricing power

Operating Margin

12.9%

Profit from core operations before interest and tax

Free Cash Flow

$3M

Positive — the business generates more cash than it spends

Revenue (TTM)

$56M

Total revenue over the last 12 months

Net Income

$9M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$18.00

Target Median

$16.00

Target Low

$15.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15

Before you go